Kiniksa Pharmaceuticals International, plc KNSA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's operating cash flow?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported operating cash flow of $50.2M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's operating cash flow changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's operating cash flow increased by 124.9% year-over-year, from $22.32M to $50.2M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's operating cash flow?
- Over 3 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's operating cash flow has grown at a 3.0% compound annual growth rate (CAGR), from -$126.3M to $137.99M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.